Abstract
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of brexanolone and related neurosteroid GABAA positive allosteric modulators in comparison with any other treatment (pharmacological, psychological, or psychosocial), placebo, or treatment as usual for postnatal depression (PND).
| Original language | English |
|---|---|
| Article number | CD014624 |
| Number of pages | 11 |
| Journal | Cochrane Database of Systematic Reviews |
| Volume | 2021 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 19 May 2021 |
Bibliographical note
Funding Information:We thank the Cochrane Common Mental Disorders (CCMD) editorial team. We thank Sarah Dawson (CCMD Information Specialist) for assistance with developing the search strategy. We and the CCMD editorial team thank the following peer reviewers for their time and comments: Lucy C Barker, Verity Westgate, Myfanwy J Williams, and Gillian Worthy. We also thank Cochrane Copy Edit Support for assistance. Cochrane Review Group funding acknowledgement: the National Institute for Health Research (NIHR) is the largest single funder of the CCMD Group. Disclaimer: the views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the NIHR, the NHS, or the Department of Health and Social Care.
Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.